Bone morphogenetic protein (BMP)

Bone morphogenetic proteins are a group of growth factors originally discovered for their ability to induce bone and cartilage formation. Most members belong to the transforming growth factor beta superfamily, except for BMP1 which is a metalloprotease with distinct function. There are at least 12 well-characterized human ligands that signal through heterotetrameric complexes composed of type I and type II serine/threonine kinase receptors on the cell surface. Upon ligand binding, these receptors activate intracellular SMAD proteins via phosphorylation; these then regulate gene expression critical for embryonic patterning, skeletal development, neurogenesis, organogenesis, tissue repair/regeneration, immune modulation, and cancer biology. Recombinant human forms are used clinically in orthopedic applications. BMP signaling is tightly regulated at multiple levels—by extracellular antagonists like Noggin as well as intracellular feedback loops—and can be targeted pharmacologically by both inhibitors and stimulators. Dysregulation has been implicated in various diseases including cancers where it may have tumor-promoting or suppressive roles depending on context.[3][6][10] Note: "Bone morphogenetic protein" refers collectively to this family; individual members such as "Bone morphogenetic protein 2" have specific functions but share core mechanisms.[5] If you require information about a specific member such as "Bone morphogenetic protein 1," please specify further.

Other names

BMPBone morphogenetic proteins (plural, for the family)Cytokines (context-dependent)Metabologens (context-dependent)[5]

Inhibition of type I BMP receptor kinase activity by small molecules blocks downstream SMAD signaling and gene transcription involved in cell differentiation and proliferation.[6][2] Some drugs act as pathway potentiators or synergizers to enhance BMP signaling.[6]